President Droupadi Murmu will visit Mumbai today, where she will dedicate CAR-T Cell Therapy to the nation at IIT Bombay. The CAR-T Cell Therapy (used to treat cancer patients) has been developed in India by IIT Bombay-incubated Company Immunoadoptive Cell Therapy (ImmunoACT).
The CAR-T Cell Therapy product has been developed as a collaborative effort between IIT Bombay and Tata Memorial Centre (TMC). Designed and developed at IIT Bombay, the therapy has undergone integrative process development and manufacturing at ImmunoACT. Clinical investigations and translational studies were conducted by teams at TMH. The CAR-T Cell Therapy product is expected to save many lives at much lower cost compared to the cost of such products available outside India.
